Cyclerion Therapeutics (NASDAQ:CYCN) Announces Quarterly Earnings Results

Cyclerion Therapeutics (NASDAQ:CYCN) issued its earnings results on Wednesday. The company reported ($0.30) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $0.08 million for the quarter. Cyclerion Therapeutics had a negative net margin of 89.51% and a negative return on equity of 22.63%.

Cyclerion Therapeutics Stock Down 11.8%

CYCN stock traded down $0.19 during midday trading on Wednesday, reaching $1.42. The stock had a trading volume of 265,268 shares, compared to its average volume of 756,706. Cyclerion Therapeutics has a twelve month low of $1.27 and a twelve month high of $9.47. The firm has a market cap of $4.74 million, a price-to-earnings ratio of -1.92 and a beta of 1.13. The business has a fifty day simple moving average of $2.28 and a two-hundred day simple moving average of $2.72.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cyclerion Therapeutics in a research report on Wednesday, November 5th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.